BioAtla Inc Share Price Today: Live Updates & Key Insights

BioAtla Inc share price today is $3.31, up -2.6%. The stock opened at $3.42 against the previous close of $3.46, with an intraday high of $3.42 and low of $3.27.

BioAtla Inc Share Price Chart

BioAtla Inc

us-stock
To Invest in {{usstockname}}
us-stock

BioAtla Inc Share Price Performance

$3.31 -0.026(-2.6%) BCAB at 27 Jul 2026 02:07 PM Biotechnology
Lowest Today 3.27
Highest Today 3.42
Today’s Open 3.42
Prev. Close 3.46
52 Week High 71.50
52 Week Low 3.12
Day’s Range: Low 3.27 High 3.42
52-Week Range: Low 3.12 High 71.50
1 day return -
1 Week return -8.69
1 month return -8.44
3 month return -24.66
6 month return +851.84
1 year return +850.76
3 year return +15.26
5 year return -91.91
10 year return -

BioAtla Inc Institutional Holdings

Millennium Management LLC 3.32

Vanguard Group Inc 2.35

Vanguard Capital Management, LLC 1.99

Acadian Asset Management LLC 1.49

Geode Capital Management, LLC 0.83

Deutsche Bank AG 0.63

Renaissance Technologies Corp 0.62

BlackRock Inc 0.58

Vanguard Institutional Extnd Mkt Idx Tr 0.55

Citadel Advisors Llc 0.53

UBS Group AG 0.45

Fidelity Extended Market Index 0.37

Marshall Wace Asset Management Ltd 0.33

Vanguard Fiduciary Trust Co 0.33

ADAR1 Capital Management LLC 0.27

State Street Corp 0.18

Xtrackers MSCI World Swap ETF 1C 0.18

Northern Trust Corp 0.12

Extended Equity Market Fund B 0.12

Extended Equity Market Fund E 0.12

Blackrock Extended Mkt Fund CF 0.12

NT Ext Equity Mkt Index Fund - NL 0.11

BlackRock Extended Equity Market Fund K 0.10

Fidelity Total Market Index 0.10

SIMPLEX TRADING, LLC 0.09

Fidelity Series Total Market Index 0.09

NT Ext Equity Mkt Index Fund - Lending 0.08

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.08

Stonepine Capital Management Llc 0.08

XTX Topco Ltd 0.07

Morgan Stanley - Brokerage Accounts 0.07

Mccormack Advisors International 0.06

Spartan Extended Market Index Pool F 0.06

NT Ext Eq Mkt Idx Fd DC Lending Tier 5 0.03

BSF Systematic US Eq Abs Ret A2 USD 0.01

U.S. Equity Market Fund 0.01

U.S. Equity Market Fund B 0.01

SSgA U.S. Total Market Index Strategy 0.01

Northern Trust Extended Eq Market Idx 0.00

Blackstone Alternative Multi-Strategy I 0.00

BioAtla Inc Market Status

Strong Buy: 2

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

BioAtla Inc Fundamentals

Market Cap 5.74 M

PB Ratio 2.681

PE Ratio 0.0

Enterprise Value 9.76 M

Total Assets 13.83 M

Volume 41612

BioAtla Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:250000 0.3M, FY20:429000 0.4M, FY19:5200000 5.2M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:250000 0.3M, FY20:429000 0.4M, FY19:5200000 5.2M

Annual Net worth FY23:-124080000 -124.1M, FY22:-105283000 -105.3M, FY21:-95406000 -95.4M, FY20:-37241000 -37.2M, FY19:-31402000 -31.4M

Quarterly Revenue Q1/2026:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:11000000 11.0M

Quarterly Profit Q1/2026:-120000 -0.1M, Q3/2025:-56000 -0.1M, Q2/2025:-567000 -0.6M, Q1/2025:-183000 -0.2M, Q3/2024:11000000 11.0M

Quarterly Net worth Q1/2026:-6344000 -6.3M, Q3/2025:-15778000 -15.8M, Q2/2025:-18711000 -18.7M, Q1/2025:-15334000 -15.3M, Q3/2024:-10586000 -10.6M

About BioAtla Inc & investment objective

Company Information BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 41

Industry Biotechnology

CEO Dr. Jay M. Short Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

BioAtla Inc FAQs

What is the share price of BioAtla Inc today?

The current share price of BioAtla Inc is $3.31.

Can I buy BioAtla Inc shares in India?

Yes, Indian investors can buy BioAtla Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy BioAtla Inc shares in India?

You can easily invest in BioAtla Inc shares from India by:

Can I buy fractional shares of BioAtla Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of BioAtla Inc?

BioAtla Inc has a market cap of $5.74 M.

In which sector does BioAtla Inc belong?

BioAtla Inc operates in the Biotechnology sector.

What documents are required to invest in BioAtla Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of BioAtla Inc?

The PE ratio of BioAtla Inc is N/A and the PB ratio is 2.68.